|
64 | 64 | "drug.id": "CHEMBL1743035", |
65 | 65 | "drug.name": "LEBRIKIZUMAB", |
66 | 66 | "drug.drugType": "Antibody", |
67 | | - "drug.mechanismsOfAction.rows": [ |
68 | | - [ |
69 | | - [ |
70 | | - "mechanismOfAction", |
71 | | - "Interleukin-13 inhibitor" |
72 | | - ] |
73 | | - ] |
74 | | - ], |
| 67 | + "drug.mechanismsOfAction.rows": "Interleukin-13 inhibitor", |
75 | 68 | "drug.description": "Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for atopic eczema and eczematoid dermatitis and 5 investigational indications.", |
76 | 69 | "drug.synonyms": [ |
77 | 70 | "Lebrikizumab", |
|
84 | 77 | "RO-5490255", |
85 | 78 | "Tnx-650" |
86 | 79 | ], |
87 | | - "drug.tradeNames": [ |
88 | | - "Ebglyss" |
89 | | - ], |
| 80 | + "drug.tradeNames": "Ebglyss", |
90 | 81 | "drug.maximumClinicalStage": "APPROVAL", |
91 | 82 | "drug.indications.rows": [ |
92 | | - [ |
93 | | - [ |
94 | | - "disease", |
95 | | - [ |
96 | | - [ |
97 | | - "id", |
98 | | - "EFO_0000274" |
99 | | - ], |
100 | | - [ |
101 | | - "name", |
102 | | - "atopic eczema" |
103 | | - ] |
104 | | - ] |
105 | | - ] |
106 | | - ], |
107 | | - [ |
108 | | - [ |
109 | | - "disease", |
110 | | - [ |
111 | | - [ |
112 | | - "id", |
113 | | - "EFO_0000768" |
114 | | - ], |
115 | | - [ |
116 | | - "name", |
117 | | - "idiopathic pulmonary fibrosis" |
118 | | - ] |
119 | | - ] |
120 | | - ] |
121 | | - ], |
122 | | - [ |
123 | | - [ |
124 | | - "disease", |
125 | | - [ |
126 | | - [ |
127 | | - "id", |
128 | | - "MONDO_0004979" |
129 | | - ], |
130 | | - [ |
131 | | - "name", |
132 | | - "asthma" |
133 | | - ] |
134 | | - ] |
135 | | - ] |
136 | | - ], |
137 | | - [ |
138 | | - [ |
139 | | - "disease", |
140 | | - [ |
141 | | - [ |
142 | | - "id", |
143 | | - "HP_0000964" |
144 | | - ], |
145 | | - [ |
146 | | - "name", |
147 | | - "Eczematoid dermatitis" |
148 | | - ] |
149 | | - ] |
150 | | - ] |
151 | | - ], |
152 | | - [ |
153 | | - [ |
154 | | - "disease", |
155 | | - [ |
156 | | - [ |
157 | | - "id", |
158 | | - "EFO_0000341" |
159 | | - ], |
160 | | - [ |
161 | | - "name", |
162 | | - "chronic obstructive pulmonary disease" |
163 | | - ] |
164 | | - ] |
165 | | - ] |
166 | | - ], |
167 | | - [ |
168 | | - [ |
169 | | - "disease", |
170 | | - [ |
171 | | - [ |
172 | | - "id", |
173 | | - "EFO_0000183" |
174 | | - ], |
175 | | - [ |
176 | | - "name", |
177 | | - "Hodgkins lymphoma" |
178 | | - ] |
179 | | - ] |
180 | | - ] |
181 | | - ], |
182 | | - [ |
183 | | - [ |
184 | | - "disease", |
185 | | - [ |
186 | | - [ |
187 | | - "id", |
188 | | - "MONDO_0004784" |
189 | | - ], |
190 | | - [ |
191 | | - "name", |
192 | | - "allergic asthma" |
193 | | - ] |
194 | | - ] |
195 | | - ] |
196 | | - ] |
| 83 | + { |
| 84 | + "id": "EFO_0000274", |
| 85 | + "name": "atopic eczema" |
| 86 | + }, |
| 87 | + { |
| 88 | + "id": "EFO_0000768", |
| 89 | + "name": "idiopathic pulmonary fibrosis" |
| 90 | + }, |
| 91 | + { |
| 92 | + "id": "MONDO_0004979", |
| 93 | + "name": "asthma" |
| 94 | + }, |
| 95 | + { |
| 96 | + "id": "HP_0000964", |
| 97 | + "name": "Eczematoid dermatitis" |
| 98 | + }, |
| 99 | + { |
| 100 | + "id": "EFO_0000341", |
| 101 | + "name": "chronic obstructive pulmonary disease" |
| 102 | + }, |
| 103 | + { |
| 104 | + "id": "EFO_0000183", |
| 105 | + "name": "Hodgkins lymphoma" |
| 106 | + }, |
| 107 | + { |
| 108 | + "id": "MONDO_0004784", |
| 109 | + "name": "allergic asthma" |
| 110 | + } |
197 | 111 | ] |
198 | 112 | }, |
199 | 113 | { |
200 | 114 | "drug.id": "CHEMBL1742985", |
201 | 115 | "drug.name": "ANRUKINZUMAB", |
202 | 116 | "drug.drugType": "Antibody", |
203 | | - "drug.mechanismsOfAction.rows": [ |
204 | | - [ |
205 | | - [ |
206 | | - "mechanismOfAction", |
207 | | - "Interleukin-13 inhibitor" |
208 | | - ] |
209 | | - ] |
210 | | - ], |
| 117 | + "drug.mechanismsOfAction.rows": "Interleukin-13 inhibitor", |
211 | 118 | "drug.description": "Antibody drug with a maximum clinical stage of Phase 2 (across all indications), with 2 investigational indications.", |
212 | 119 | "drug.synonyms": [ |
213 | 120 | "Anrukinzumab", |
214 | 121 | "IMA-638" |
215 | 122 | ], |
216 | | - "drug.tradeNames": [], |
| 123 | + "drug.tradeNames": null, |
217 | 124 | "drug.maximumClinicalStage": "PHASE_2", |
218 | 125 | "drug.indications.rows": [ |
219 | | - [ |
220 | | - [ |
221 | | - "disease", |
222 | | - [ |
223 | | - [ |
224 | | - "id", |
225 | | - "MONDO_0004979" |
226 | | - ], |
227 | | - [ |
228 | | - "name", |
229 | | - "asthma" |
230 | | - ] |
231 | | - ] |
232 | | - ] |
233 | | - ], |
234 | | - [ |
235 | | - [ |
236 | | - "disease", |
237 | | - [ |
238 | | - [ |
239 | | - "id", |
240 | | - "EFO_0000729" |
241 | | - ], |
242 | | - [ |
243 | | - "name", |
244 | | - "ulcerative colitis" |
245 | | - ] |
246 | | - ] |
247 | | - ] |
248 | | - ] |
| 126 | + { |
| 127 | + "id": "MONDO_0004979", |
| 128 | + "name": "asthma" |
| 129 | + }, |
| 130 | + { |
| 131 | + "id": "EFO_0000729", |
| 132 | + "name": "ulcerative colitis" |
| 133 | + } |
249 | 134 | ] |
250 | 135 | } |
251 | | - ] |
| 136 | + ] |
252 | 137 | }, |
253 | 138 | "test_opentargets_expression": { |
254 | 139 | "function_call_to_reproduce": "output = opentargets(ensembl_id='ENSG00000169194', resource='expression', limit=2, json=True, verbose=False); print(json.dumps(output, indent=2))", |
|
298 | 183 | "limit": 2 |
299 | 184 | }, |
300 | 185 | "expected_result": [ |
301 | | - { |
302 | | - "tissueId": "UBERON_0002367", |
303 | | - "tissueName": "prostate gland", |
304 | | - "cellLineName": "DU 145", |
305 | | - "expression": 0.0343439169, |
306 | | - "diseaseFromSource": "Prostate Adenocarcinoma", |
307 | | - "depmapId": "ACH-000979", |
308 | | - "geneEffect": -0.1433678865 |
309 | | - }, |
310 | | - { |
311 | | - "tissueId": "UBERON_0002367", |
312 | | - "tissueName": "prostate gland", |
313 | | - "cellLineName": "WPE1-NA22", |
314 | | - "expression": 0.0291899424, |
315 | | - "diseaseFromSource": "Non-Cancerous", |
316 | | - "depmapId": "ACH-001422", |
317 | | - "geneEffect": 0.069347702 |
318 | | - } |
319 | | - ] |
| 186 | + { |
| 187 | + "score": 0.999, |
| 188 | + "count": 3, |
| 189 | + "sourceDatabase": "string", |
| 190 | + "intA": "ENSP00000304915", |
| 191 | + "intABiologicalRole": "unspecified role", |
| 192 | + "intB": "ENSP00000361004", |
| 193 | + "intBBiologicalRole": "unspecified role", |
| 194 | + "targetA.id": "ENSG00000169194", |
| 195 | + "targetA.approvedSymbol": "IL13", |
| 196 | + "speciesA.taxonId": 134, |
| 197 | + "targetB.id": "ENSG00000123496", |
| 198 | + "targetB.approvedSymbol": "IL13RA2", |
| 199 | + "speciesB.taxonId": 134 |
| 200 | + }, |
| 201 | + { |
| 202 | + "score": 0.999, |
| 203 | + "count": 3, |
| 204 | + "sourceDatabase": "string", |
| 205 | + "intA": "ENSP00000304915", |
| 206 | + "intABiologicalRole": "unspecified role", |
| 207 | + "intB": "ENSP00000360730", |
| 208 | + "intBBiologicalRole": "unspecified role", |
| 209 | + "targetA.id": "ENSG00000169194", |
| 210 | + "targetA.approvedSymbol": "IL13", |
| 211 | + "speciesA.taxonId": 134, |
| 212 | + "targetB.id": "ENSG00000131724", |
| 213 | + "targetB.approvedSymbol": "IL13RA1", |
| 214 | + "speciesB.taxonId": 134 |
| 215 | + } |
| 216 | + ] |
320 | 217 | }, |
321 | 218 | "test_opentargets_pharmacogenetics": { |
322 | 219 | "function_call_to_reproduce": "output = opentargets(ensembl_id='ENSG00000169194', resource='pharmacogenetics', limit=2, json=True, verbose=False); print(json.dumps(output, indent=2))", |
|
360 | 257 | "variantFunctionalConsequence.id": "SO:0001627", |
361 | 258 | "variantFunctionalConsequence.label": "intron_variant" |
362 | 259 | } |
363 | | - ] |
| 260 | + ] |
364 | 261 | }, |
365 | 262 | "test_opentargets_tractability": { |
366 | 263 | "function_call_to_reproduce": "output = opentargets(ensembl_id='ENSG00000169194', resource='tractability', limit=2, json=True, verbose=False); print(json.dumps(output, indent=2))", |
|
0 commit comments